Thank You slugobear. coldly rational is the appropriate way to invest. I am not a scientist, but a negotiator. One needs to know with as much certainty as they possibly can ascertain what the probabilities are for the outcome they seek. In MNKD, I found, what I believe you found, after much DD, a major disruption to the status quo. That is why I selected MNKD. I'm fully loaded as well. I am not a cultist and am not married to this stock as shorts would like us to believe. I am "coldly rational". All the best.
$4.17 is my average too. And I'm going to stay around also.
Sentiment: Strong Buy
Ha! That's hysterical. If they keep posting on webmd at that rate I predict their server crashes by year end.
Interesting, all RAA rx's are down. How can this be as these are needed maintenance medications? Is it do to some diabetics trialing the Afrezza samples before renewing their injectable RAA scripts? Its a puzzlement. Whatever, we really won't see much movement until the additional lines are producing at Danbury and Direct to Consumer Advertizing begins. Until then, patience.
a thumbs down. Ignore them and their many aliases entirely. The silence will be deafening for them. They are like brat children whining for attention. Treat them as you would treat those brats.
Many have gone over and seen the glowing Afrezza reviews thus far on WebMD. For anyone who has doubts about Type 2's acceptance of Afrezza, check out the reviews on Metformin. They will blow your (not your mind).Star ratings, 3 Effectiveness, 4 Ease of Use (its a pill) and 3 Satisfaction. Afrezza is running 5's across the board. Have patience as the patients will come, in droves for Afrezza
agreed matese, mnkd is doing what they're supposed to do, business, not pumping
they don't even have to worry about sales. That's Sanofi's lift. MNKD needs to focus on production and the next technosphere application
sorry itell, but I have to point out a correction;
."insurance companies..(which you don't use if using the free Afrezza Savings Card) "
These promotion cards are designed to use with prescription coverage. The first month Sanofi covers you co-payment. then refils no more than $30 co-pay. Both have a maximum benefit of $150